| 書目名稱 | Lung Cancer and Personalized Medicine | | 副標(biāo)題 | Current Knowledge an | | 編輯 | Aamir Ahmad,Shirish Gadgeel | | 視頻video | http://file.papertrans.cn/590/589080/589080.mp4 | | 概述 | Succintly combines the most current research on lung cancer from epidemiology to recent breakthroughs in personalized therapies.Explores current targets, molecular profiling and biomarkers in lung can | | 叢書名稱 | Advances in Experimental Medicine and Biology | | 圖書封面 |  | | 描述 | .This, the first of two volumes on personalized medicine in lung cancer, touches on the core issues related to the understanding of lung cancer—statistics and epidemiology of lung cancer—along with the incidence of lung cancer in non-smokers. A major focus of this volume is the state of current therapies against lung cancer—immune, targeted therapies against EGFR TKIs, KRAS, ALK, angiogenesis; the associated challenges, especially resistance mechanisms; and recent progress in targeted drug development based on metal chemistry. Chapters are written by some of the leading experts in the field, who provide a better understanding of lung cancer, the factors that make it lethal, and current research focused on developing personalized treatment plans. With a unique mix of topics, this volume summarizes the current state-of-knowledge on lung cancer and the available therapies.. | | 出版日期 | Book 2016 | | 關(guān)鍵詞 | ALK signaling; EGFR signaling; k-ras; lung cancer therapy; personalized therapy; small cell lung cancer | | 版次 | 1 | | doi | https://doi.org/10.1007/978-3-319-24223-1 | | isbn_softcover | 978-3-319-79592-8 | | isbn_ebook | 978-3-319-24223-1Series ISSN 0065-2598 Series E-ISSN 2214-8019 | | issn_series | 0065-2598 | | copyright | The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerl |
The information of publication is updating
|
|
|Archiver|手機(jī)版|小黑屋|
派博傳思國際
( 京公網(wǎng)安備110108008328)
GMT+8, 2025-10-8 09:30
發(fā)表于 2025-3-21 16:59:07
